Total Payments
$9,899
2024 Payments
$479.73
Companies
31
Transactions
299
Medicare Patients
5,021
Medicare Billing
$531,779
Payment Breakdown by Category
Food & Beverage$5,206 (52.6%)
Other$2,175 (22.0%)
Travel$1,529 (15.4%)
Education$696.07 (7.0%)
Research$293.00 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,206 | 265 | 52.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,175 | 2 | 22.0% |
| Travel and Lodging | $1,529 | 7 | 15.4% |
| Education | $696.07 | 24 | 7.0% |
| Unspecified | $293.00 | 1 | 3.0% |
Payments by Type
General
$9,606
298 transactions
Research
$293.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,636 | 21 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,317 | 86 | $0 (2024) |
| Theravance Biopharma Inc. | $951.96 | 4 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $834.26 | 6 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $768.08 | 39 | $0 (2022) |
| Actelion Pharmaceuticals US, Inc. | $501.58 | 25 | $0 (2024) |
| United Therapeutics Corporation | $435.42 | 24 | $0 (2021) |
| Insmed, Inc. | $352.96 | 9 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $293.00 | 1 | $0 (2019) |
| GENZYME CORPORATION | $277.98 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $479.73 | 18 | GlaxoSmithKline, LLC. ($200.16) |
| 2023 | $510.45 | 26 | GlaxoSmithKline, LLC. ($172.80) |
| 2022 | $443.51 | 18 | Boehringer Ingelheim Pharmaceuticals, Inc. ($175.95) |
| 2021 | $376.83 | 22 | Insmed, Inc. ($146.61) |
| 2020 | $603.46 | 30 | GlaxoSmithKline, LLC. ($160.93) |
| 2019 | $1,832 | 75 | GlaxoSmithKline, LLC. ($365.39) |
| 2018 | $720.56 | 53 | Boehringer Ingelheim Pharmaceuticals, Inc. ($132.95) |
| 2017 | $4,932 | 57 | AstraZeneca Pharmaceuticals LP ($2,283) |
All Payment Transactions
299 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $28.70 | General |
| Category: NEUROLOGY | ||||||
| 10/31/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $26.24 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $1.11 | General |
| Category: IMMUNOLOGY | ||||||
| 09/03/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: IMMUNOLOGY | ||||||
| 08/20/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: RESPIRATORY | ||||||
| 08/13/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $23.21 | General |
| Category: IMMUNOLOGY | ||||||
| 07/24/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Cardiology | ||||||
| 07/09/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: IMMUNOLOGY | ||||||
| 06/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $21.95 | General |
| Category: IMMUNOLOGY | ||||||
| 04/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $130.17 | General |
| 04/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $42.79 | General |
| Category: Immunology | ||||||
| 04/04/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: IMMUNOLOGY | ||||||
| 03/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: RESPIRATORY | ||||||
| 03/14/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $10.10 | General |
| Category: Respiratory | ||||||
| 02/22/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: IMMUNOLOGY | ||||||
| 02/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.50 | General |
| Category: Immunology | ||||||
| 01/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $7.30 | General |
| Category: IMMUNOLOGY | ||||||
| 01/04/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $26.36 | General |
| Category: Pulmonology | ||||||
| 12/14/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.99 | General |
| Category: Immunology | ||||||
| 11/21/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $14.62 | General |
| Category: HFCWO | ||||||
| 11/16/2023 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $8.61 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2023 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/20/2023 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $22.81 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: RESPIRATORY | ||||||
| 09/28/2023 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $293.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,242 | 3,127 | $333,674 | $128,032 |
| 2022 | 17 | 1,215 | 1,648 | $347,274 | $138,333 |
| 2021 | 19 | 1,372 | 1,828 | $362,467 | $152,059 |
| 2020 | 20 | 1,192 | 1,671 | $299,791 | $113,355 |
Total Patients
5,021
Total Services
8,274
Medicare Billing
$531,779
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 192 | 404 | $117,639 | $54,599 | 46.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 172 | 256 | $55,470 | $23,437 | 42.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 62 | 62 | $25,811 | $10,250 | 39.7% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 155 | 166 | $23,731 | $6,840 | 28.8% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 151 | 163 | $23,359 | $6,442 | 27.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 40 | 57 | $12,705 | $5,414 | 42.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 35 | $14,738 | $4,359 | 29.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 118 | 124 | $17,831 | $3,276 | 18.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 14 | 19 | $11,033 | $3,161 | 28.7% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 68 | 92 | $5,244 | $2,329 | 44.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 33 | $5,159 | $1,959 | 38.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $4,329 | $1,726 | 39.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 71 | 76 | $7,085 | $1,500 | 21.2% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 29 | 34 | $3,536 | $855.72 | 24.2% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2023 | 18 | 18 | $792.00 | $570.96 | 72.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 18 | 18 | $702.00 | $519.66 | 74.0% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 21 | 27 | $1,956 | $379.75 | 19.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 18 | 26 | $1,050 | $267.19 | 25.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 16 | 1,504 | $1,504 | $147.30 | 9.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 175 | 312 | $81,432 | $41,737 | 51.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 196 | 321 | $61,953 | $29,786 | 48.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 42 | 91 | $49,595 | $16,068 | 32.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 80 | 127 | $25,781 | $10,167 | 39.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 59 | 61 | $24,217 | $9,066 | 37.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 52 | 52 | $19,916 | $8,591 | 43.1% |
About Dr. Rachel Nisbet, M.D
Dr. Rachel Nisbet, M.D is a Internal Medicine healthcare provider based in Dacula, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/02/2008. The National Provider Identifier (NPI) number assigned to this provider is 1609051218.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rachel Nisbet, M.D has received a total of $9,899 in payments from pharmaceutical and medical device companies, with $479.73 received in 2024. These payments were reported across 299 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($5,206).
As a Medicare-enrolled provider, Nisbet has provided services to 5,021 Medicare beneficiaries, totaling 8,274 services with total Medicare billing of $531,779. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Critical Care Medicine, Pulmonary Disease
- Location Dacula, GA
- Active Since 01/02/2008
- Last Updated 10/07/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1609051218
Products in Payments
- BEVESPI AEROSPHERE (Drug) $2,267
- TRELEGY ELLIPTA (Drug) $514.42
- NUCALA (Biological) $475.54
- FEVIPIPRANT (Drug) $473.26
- Arikayce (Drug) $352.96
- OFEV (Drug) $318.71
- Fluticasone Propionate and Salmeterol (Drug) $293.00
- UPTRAVI (Drug) $281.09
- DUPIXENT (Biological) $264.07
- Adempas (Drug) $260.95
- ORENITRAM (Drug) $258.38
- ANORO (Drug) $173.30
- STIOLTO RESPIMAT (Drug) $173.09
- OPSUMIT (Drug) $168.57
- Zemaira (Biological) $166.24
- DUPIXENT (Drug) $132.51
- Prolastin-C Liquid (Biological) $129.70
- The Vest System Model 105 Home Care (Device) $108.88
- LINX Reflux Management System (Device) $105.52
- FASENRA (Drug) $103.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Dacula
Dr. Holly Corley, M.d, M.D
Internal Medicine — Payments: $9,265
Internal Medicine $9,265
Dr. Rami Arfoosh, M.d, M.D
Internal Medicine — Payments: $9,167
Internal Medicine $9,167
Dr. Shashvat Sukhal, M.d, M.D
Internal Medicine — Payments: $5,527
Internal Medicine $5,527
Dr. Daren Wannamaker, Do, DO
Internal Medicine — Payments: $1,456
Internal Medicine $1,456
Zhuocheng Su, Do, DO
Internal Medicine — Payments: $1,382
Internal Medicine $1,382
Jia Wen Lee, Do, DO
Internal Medicine — Payments: $985.08
Internal Medicine $985.08